ABUS vs NVST · P/E 5.4, rev $6.2M vs P/E 56, rev $2.51B
Arbutus Biopharma Corp (ABUS) versus Envista Holdings Corp (NVST) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Envista Holdings Corp (NVST) is a medical instruments & supplies company listed on US.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported NVST revenue for 2024-12-31 was $2.51B. Net income was -$1.12B. Revenue was down 2.2% from 2023-12-31 to 2024-12-31. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. NVST currently screens at market cap $3.72B and trailing P/E 55.8.
Not investment advice. Open the ABUS and NVST stock pages for the full models.
Not investment advice.